Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a c...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734738/ |
| id |
pubmed-4734738 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-47347382016-02-11 Emerging treatments in Castleman disease – a critical appraisal of siltuximab Koff, Jean L Lonial, Sagar Review Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD. Dove Medical Press 2016-01-25 /pmc/articles/PMC4734738/ /pubmed/26869762 http://dx.doi.org/10.2147/BTT.S60523 Text en © 2016 Koff and Lonial. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Koff, Jean L Lonial, Sagar |
| spellingShingle |
Koff, Jean L Lonial, Sagar Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| author_facet |
Koff, Jean L Lonial, Sagar |
| author_sort |
Koff, Jean L |
| title |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_short |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_full |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_fullStr |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_full_unstemmed |
Emerging treatments in Castleman disease – a critical appraisal of siltuximab |
| title_sort |
emerging treatments in castleman disease – a critical appraisal of siltuximab |
| description |
Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD. |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734738/ |
| _version_ |
1613531131882242048 |